{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:13:32Z","timestamp":1789049612120,"version":"build-2803163510"},"reference-count":53,"publisher":"Bioscientifica","issue":"9","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Post-cycle therapy (PCT) refers to the use of pharmacological agents \u2013 most commonly selective estrogen receptor modulators (SERMs), human chorionic gonadotropin (hCG), and aromatase inhibitors (AIs) \u2013 after cessation of androgen abuse to accelerate recovery of the hypothalamic\u2013pituitary\u2013gonadal (HPG) axis. Exogenous androgens suppress endogenous testosterone production through negative feedback, often resulting in a transient hypogonadal state that may persist for weeks to months, and occasionally longer, depending on cycle characteristics and individual factors. The rationale of PCT is to mitigate this suppression and reduce symptoms of androgen deficiency. However, evidence supporting its use is limited, with most data derived from observational studies or extrapolated from other forms of secondary hypogonadism. While some studies suggest that PCT may accelerate short-term hormonal and seminal recovery, spontaneous recovery occurs in the majority of individuals within months after cessation. Three perspectives can be distinguished. In real-world practice, PCT is widely used, often without medical supervision, driven by cultural norms and concerns about symptom persistence. From an academic standpoint, PCT is generally not recommended because of uncertain benefits and potential risks. A third perspective describes a pragmatic rationale for considering a short course of PCT in carefully selected individuals with significant symptom burden or risk of relapse into androgen abuse, while acknowledging that this approach is not supported by robust clinical evidence. This review aims to clarify the rationale, evidence gaps, and clinical implications of these perspectives to support informed clinical decision-making.<\/jats:p>","DOI":"10.1530\/ec-26-0319","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:15:05Z","timestamp":1787739305000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":0,"title":["Post-cycle therapy after androgen abuse: a narrative review of mechanisms, evidence, and clinical perspectives"],"prefix":"10.1530","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1635-1203","authenticated-orcid":true,"given":"Diederik L","family":"Smit","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Zaandam Medical Centre 1 , ,","place":["Zaandam, the Netherlands"]},{"name":"Android Health Clinic, Department of Performance and Image-enhancing Drugs Research 2 , ,","place":["Utrecht, the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tijs","family":"Verdegaal","sequence":"additional","affiliation":[{"name":"Android Health Clinic, Department of Performance and Image-enhancing Drugs Research 2 , ,","place":["Utrecht, the Netherlands"]},{"name":"Department of Internal Medicine, Spaarne Gasthuis 3 , ,","place":["Haarlem, the Netherlands"]},{"name":"Department of Endocrinology and Metabolism, Amsterdam UMC 4 , ,","place":["Amsterdam, the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6054-8762","authenticated-orcid":true,"given":"Peter","family":"Bond","sequence":"additional","affiliation":[{"name":"Android Health Clinic, Department of Performance and Image-enhancing Drugs Research 2 , ,","place":["Utrecht, the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2224-8659","authenticated-orcid":true,"given":"Willem","family":"de Ronde","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Spaarne Gasthuis 3 , ,","place":["Haarlem, the Netherlands"]},{"name":"Department of Endocrinology and Metabolism, Amsterdam UMC 4 , ,","place":["Amsterdam, the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"2026091009321078700_bib25","article-title":"Anabolic androgenic steroid use population size estimation: findings from a systematic review","volume":"245","author":"Hope","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"2026091009321078700_bib44","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.annepidem.2014.01.009","article-title":"The global epidemiology of anabolic androgenic steroid use: a meta-analysis and meta-regression analysis","volume":"24","author":"Sagoe","year":"2014","journal-title":"Ann Epidemiol"},{"key":"2026091009321078700_bib3","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/CIRCULATIONAHA.116.026945","article-title":"Cardiovascular toxicity of illicit anabolic-androgenic steroid use","volume":"135","author":"Baggish","year":"2017","journal-title":"Circulation"},{"key":"2026091009321078700_bib57","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.drugalcdep.2015.04.013","article-title":"Anabolic steroids and cardiovascular risk: a national population-based cohort study","volume":"152","author":"Thiblin","year":"2015","journal-title":"Drug Alcohol Depend"},{"key":"2026091009321078700_bib61","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.124.071117","article-title":"Cardiovascular disease in anabolic androgenic steroid users","volume":"151","author":"Windfeld-Mathiasen","year":"2025","journal-title":"Circulation"},{"key":"2026091009321078700_bib33","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/1008-682X.173938","article-title":"Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use","volume":"18","author":"Coward","year":"2016","journal-title":"Asian J Androl"},{"key":"2026091009321078700_bib45","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz324","article-title":"Rate and extent of recovery from reproductive and cardiac dysfunction due to androgen abuse in men","volume":"105","author":"Shankara-Narayana","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026091009321078700_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2008.05.004","article-title":"Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?","volume":"98","author":"Kanayama","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"2026091009321078700_bib38","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1210\/er.2013-1058","article-title":"Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement","volume":"35","author":"Pope","year":"2014","journal-title":"Endocr Rev"},{"key":"2026091009321078700_bib26","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/add.12850","article-title":"Prolonged hypogonadism in males following withdrawal from anabolic-androgenic steroids: an under-recognized problem","volume":"110","author":"Kanayama","year":"2015","journal-title":"Addiction"},{"key":"2026091009321078700_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1621558","article-title":"Prolonged post-androgen abuse hypogonadism: potential mechanisms and a proposed standardized diagnosis (PPAAH)","volume":"16","author":"van Os","year":"2025","journal-title":"Front Endocrinol"},{"key":"2026091009321078700_bib50","first-page":"167","article-title":"Outpatient clinic for users of anabolic androgenic steroids: an overview","volume":"76","author":"Smit","year":"2018","journal-title":"Neth J Med"},{"key":"2026091009321078700_bib48","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/humrep\/deaa366","article-title":"Disruption and recovery of testicular function during and after androgen abuse: the HAARLEM study","volume":"36","author":"Smit","year":"2021","journal-title":"Hum Reprod"},{"key":"2026091009321078700_bib54","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0358","article-title":"Physical, psychological and biochemical recovery from anabolic steroid-induced hypogonadism: a scoping review","volume":"12","author":"Solanki","year":"2023","journal-title":"Endocr Connect"},{"key":"2026091009321078700_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1059473","article-title":"Anabolic-androgenic steroids: how do they work and what are the risks?","volume":"13","author":"Bond","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026091009321078700_bib47","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/sms.13592","article-title":"Baseline characteristics of the HAARLEM study: 100 male amateur athletes using anabolic androgenic steroids","volume":"30","author":"Smit","year":"2020","journal-title":"Scand J Med Sci Sports"},{"key":"2026091009321078700_bib1","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1210\/jc.2018-01882","article-title":"Diagnosis and management of anabolic androgenic steroid use","volume":"104","author":"Anawalt","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026091009321078700_bib51","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1210\/clinem\/dgad475","article-title":"Predictors of ongoing androgen abuse: a prospective 2-year follow up of 100 male androgen abusers","volume":"109","author":"Smit","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026091009321078700_bib32","article-title":"Physiology of GnRH and Gonadotrophin secretion","volume-title":"Endotext [Internet]","author":"Marques","year":"2000"},{"key":"2026091009321078700_bib37","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1210\/jc.2007-2156","article-title":"Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men","volume":"93","author":"Pitteloud","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2026091009321078700_bib11","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa191","article-title":"Androgen suppresses in vivo and in vitro LH pulse secretion and neural Kiss1 and Tac2 gene expression in female mice","volume":"161","author":"Esparza","year":"2020","journal-title":"Endocrinology"},{"key":"2026091009321078700_bib35","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqad194","article-title":"KNDy neurons of the hypothalamus and their role in GnRH pulse generation: an update","volume":"165","author":"Moore","year":"2023","journal-title":"Endocrinology"},{"key":"2026091009321078700_bib46","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/humupd\/dmu009","article-title":"The kisspeptin-GnRH pathway in human reproductive health and disease","volume":"20","author":"Skorupskaite","year":"2014","journal-title":"Hum Reprod Update"},{"key":"2026091009321078700_bib34","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1210\/en.2012-1045","article-title":"Arcuate kisspeptin\/neurokinin B\/dynorphin (KNDy) neurons mediate the estrogen suppression of gonadotropin secretion and body weight","volume":"153","author":"Mittelman-Smith","year":"2012","journal-title":"Endocrinology"},{"key":"2026091009321078700_bib23","first-page":"3027","article-title":"Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback","volume":"85","author":"Hayes","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2026091009321078700_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1210\/me.2011-1015","article-title":"Androgen receptor repression of GnRH gene transcription","volume":"26","author":"Brayman","year":"2012","journal-title":"Mol Endocrinol"},{"key":"2026091009321078700_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MED.0000000000000406","article-title":"Recovery of reproductive function following androgen abuse","volume":"25","author":"Christou","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2026091009321078700_bib30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4111\/icu.2018.59.1.18","article-title":"Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer","volume":"59","author":"Nam","year":"2018","journal-title":"Investig Clin Urol"},{"key":"2026091009321078700_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110256","article-title":"Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials","volume":"195","author":"Nabid","year":"2024","journal-title":"Radiother Oncol"},{"key":"2026091009321078700_bib29","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(06)68614-5","article-title":"Hormonal Male Contraception Summit Group. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis","volume":"367","author":"Liu","year":"2006","journal-title":"Lancet"},{"key":"2026091009321078700_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1530\/EJE-21-0608","article-title":"Recovery of male reproductive endocrine function after ceasing prolonged testosterone undecanoate injections","volume":"186","author":"Handelsman","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"2026091009321078700_bib49","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/sms.13843","article-title":"Positive and negative side effects of androgen abuse. The HAARLEM study: a one-year prospective cohort study in 100 men","volume":"31","author":"Smit","year":"2021","journal-title":"Scand J Med Sci Sports"},{"key":"2026091009321078700_bib8","article-title":"Characterisation of Leydig cell dysfunction in previous illicit androgen users","volume":"7","author":"Bulut","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026091009321078700_bib12","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1055\/s-0034-1398492","article-title":"The response to gonadotropin-releasing hormone and hCG in men with prior chronic androgen steroid abuse and clinical hypogonadism","volume":"47","author":"Flanagan","year":"2015","journal-title":"Horm Metab Res"},{"key":"2026091009321078700_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1530\/eje.0.1470617","article-title":"Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone","volume":"147","author":"Depenbusch","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"2026091009321078700_bib13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ejendo\/lvad164","article-title":"Factors predicting normalization of reproductive hormones after cessation of anabolic-androgenic steroids in men: a single center retrospective study","volume":"189","author":"Grant","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"2026091009321078700_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/joim.20040","article-title":"Effects of letrozole therapy in former users of anabolic steroids: a randomized clinical trial","volume":"297","author":"Rasmussen","year":"2025","journal-title":"J Intern Med"},{"key":"2026091009321078700_bib6","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s11606-021-06751-3","article-title":"Harm reduction in male patients actively using anabolic androgenic steroids (AAS) and performance-enhancing drugs (PEDs): a review","volume":"36","author":"Bonnecaze","year":"2021","journal-title":"J Gen Intern Med"},{"key":"2026091009321078700_bib41","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.fertnstert.2014.02.002","article-title":"Anabolic steroid-induced hypogonadism: diagnosis and treatment","volume":"101","author":"Rahnema","year":"2014","journal-title":"Fertil Steril"},{"key":"2026091009321078700_bib14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13011-023-00573-8","article-title":"The use of post cycle therapy is associated with reduced withdrawal symptoms from anabolic androgenic steroid use: a survey of 470 men","volume":"18","author":"Grant","year":"2023","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2026091009321078700_bib2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/bju.70059","article-title":"Post-cycle therapy after short-term anabolic-androgenic steroid use: comparative outcomes in recreational bodybuilders","volume":"137","author":"Ibis","year":"2025","journal-title":"BJU Int"},{"key":"2026091009321078700_bib16","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgag110","article-title":"Clinical features of androgen abuse withdrawal in men during the first year of cessation: a community dwelling study","volume":"111","author":"Grant","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"2026091009321078700_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.peh.2024.100288","article-title":"Navigating non-medical androgen use: towards a harm reduction paradigm","volume":"12","author":"Smit","year":"2024","journal-title":"Perform Enhanc Health"},{"key":"2026091009321078700_bib60","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/jsm.12890","article-title":"The use of HCG-based combination therapy for recovery of spermatogenesis after testosterone use","volume":"12","author":"Wenker","year":"2015","journal-title":"J Sex Med"},{"key":"2026091009321078700_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2025.1536858","article-title":"Illegal and falsified medicines self-administrated in not approved post-cycle therapy after the cessation of anabolic-androgenic steroids - qualitative analysis","volume":"13","author":"Blazewicz","year":"2025","journal-title":"Front Chem"},{"key":"2026091009321078700_bib43","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.therap.2022.03.004","article-title":"Doping with aromatase inhibitors and oestrogen receptor modulators in steroid users: analysis of a forum to identify dosages, durations and adverse drug reactions","volume":"77","author":"Rochoy","year":"2022","journal-title":"Therapie"},{"key":"2026091009321078700_bib40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.sxmr.2020.08.003","article-title":"Efficacy of non-testosterone-based treatment in hypogonadal men: a review","volume":"9","author":"Raheem","year":"2021","journal-title":"Sex Med Rev"},{"key":"2026091009321078700_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.peh.2024.100283","article-title":"Clomiphene citrate and optional human chorionic gonadotropin for treating male hypogonadism arising from long-term anabolic-androgenic steroid use\u2014A pilot study","volume":"12","author":"Henriksen","year":"2024","journal-title":"Perform Enhanc Health"},{"key":"2026091009321078700_bib15","article-title":"Survey of endocrinologists managing recovery from anabolic androgenic steroid induced hypogonadism","volume":"4","author":"Grant","year":"2023","journal-title":"Reprod Fertil"},{"key":"2026091009321078700_bib31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12902-024-01612-6","article-title":"Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis","volume":"24","author":"Nassar","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"2026091009321078700_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.peh.2016.11.002","article-title":"Post-cycle therapy for performance and image enhancing drug users: a qualitative investigation","volume":"5","author":"Griffiths","year":"2017","journal-title":"Perform Enhanc Health"},{"key":"2026091009321078700_bib42","first-page":"66","article-title":"The role of estrogen modulators in Male hypogonadism and infertility","volume":"18","author":"Rambhatla","year":"2016","journal-title":"Rev Urol"},{"key":"2026091009321078700_bib56","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/andr.13373","article-title":"Selective modulation of estrogen receptor in obese men with androgen deficiency: a systematic review and meta-analysis","volume":"11","author":"Tienforti","year":"2023","journal-title":"Andrology"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-26-0319\/524264\/ec-26-0319.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-26-0319\/524264\/ec-26-0319.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:32:25Z","timestamp":1789047145000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/15\/9\/e260319\/78085\/Post-cycle-therapy-after-androgen-abuse-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-26-0319","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"e260319"}}